Parallax Volatility Advisers’s Pacific Biosciences PACB Stock Holding History

Parallax Volatility Advisers’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-529,300	Closed	-$5.19M	–	2216
2023 Q4	$5.19M	Buy	+529,300	New	+$4.33M	0.01%	822
2023 Q1	–	Sell	-24,800	Closed	-$203K	–	3049
2022 Q4	$203K	Buy	+24,800	New	+$214K	﹤0.01%	2138
2022 Q1	–	Sell	-44,400	Closed	-$909K	–	3055
2021 Q4	$909K	Buy	+44,400	New	+$1.07M	﹤0.01%	1305
2021 Q3	–	Sell	-15,400	Closed	-$538K	–	2103
2021 Q2	$538K	Sell	15,400 -2,800	-15%	-$81.4K	﹤0.01%	1139
2021 Q1	$607K	Buy	+18,200	New	+$637K	﹤0.01%	922

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Parallax Volatility Advisers's PACB Position: Q1 2023 in Review

Parallax Volatility Advisers sold out of Pacific Biosciences (PACB) in Q1 2023, closing a stake of 993 shares — an estimated $8.12K sold.

Parallax Volatility Advisers first reported a position in PACB in Q4 2017 and held it in 7 quarters. The position peaked at $1.05M in Q3 2022. 259 funds tracked by Wall St. Rank hold PACB as of Q1 2023.

Parallax Volatility Advisers reported no remaining Pacific Biosciences position as of Q1 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 993 Pacific Biosciences shares in Q1 2023, an estimated $8.12K.
Parallax Volatility Advisers first reported a position in Pacific Biosciences in Q4 2017 and held it in 7 quarters.
Parallax Volatility Advisers's Pacific Biosciences position peaked at $1.05M in Q3 2022.
259 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2023.

Based on Parallax Volatility Advisers's 13F filing for Q1 2023, filed 15 May 2023.